NovoCure Ltd. (NVCR)
Market Closed
22 Jul, 20:00
$
15. 57
-0.43
-2.6875%
After Hours
$
+1.33 +8.5421% 16. 90
1.84B Market Cap
- P/E Ratio
- Div Yield
1.01M Volume
-2.03 Eps
$ 16
Previous Close 
Want to track NVCR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C.
Seekingalpha | 1 year ago
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
Zacks | 1 year ago
